Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04731844 · OUTCOME

Percentage of Participants Without Disease Progression or Death at 12 Months

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer · Source last updated 2026-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
From enrollment to 12 months

What was measured

Proportion of participants who remained free from disease progression or death from any cause at 12 months after enrollment. Participants without documented progression or death by 12 months were considered progression-free.

Analysis population: All enrolled participants

Groups in this outcome

Prostate Cancer

Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.

Smoldering Multiple Myeloma (SMM)

Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.

Monoclonal Gammopathy of Unknown Significance (MGUS)

Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Prostate Cancer12
Smoldering Multiple Myeloma (SMM)8
Monoclonal Gammopathy of Unknown Significance (MGUS)9

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Prostate Cancer9Not reportedNot reportedNot reportedNot reported
Smoldering Multiple Myeloma (SMM)6Not reportedNot reportedNot reportedNot reported
Monoclonal Gammopathy of Unknown Significance (MGUS)3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        6
      3. group Id
        OG002
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    2. group Id
      OG001
      value
      8
    3. group Id
      OG002
      value
      9
    units
    Participants
description
Proportion of participants who remained free from disease progression or death from any cause at 12 months after enrollment. Participants without documented progression or death by 12 months were considered progression-free.
groups
  1. description
    Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    OG000
    title
    Prostate Cancer
  2. description
    Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    OG001
    title
    Smoldering Multiple Myeloma (SMM)
  3. description
    Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    OG002
    title
    Monoclonal Gammopathy of Unknown Significance (MGUS)
param Type
NUMBER
population Description
All enrolled participants
reporting Status
POSTED
time Frame
From enrollment to 12 months
title
Percentage of Participants Without Disease Progression or Death at 12 Months
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice